Lexaria Bioscience CORP (LEXX) — Institutional Investor Activity (Q2 2026)

LEXX ranks #7400 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

LEXX is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

31 institutions disclose a position in LEXX, but none treat it as a major bet — even Invenomic Capital Management LP, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Northern Trust CORP has added to its LEXX position for two straight quarters, increasing it by $11.0K to reach $22.3K today.

UBS Group AG has trimmed its LEXX position for two straight quarters, cutting it by $196.6K while still holding $26.3K.

LEXX reported a net loss of $7.7M over the trailing twelve months.

• Not yet profitable — net loss of $7.7M over the trailing twelve months
• Revenue declined 68.5% year over year
• Net income improved year over year, from -$11.4M to -$7.7M
• Operating cash flow was negative, using $10.5M in cash
• Current ratio of 2.32x — enough short-term assets to cover short-term liabilities
• Liabilities run 80.39x equity — a highly leveraged balance sheet worth noting